Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease

Published:2015-05-20 Issue:2 Volume:42 Page:188-202
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Rosario M.¹,Dirks N. L.²,Gastonguay M. R.²,Fasanmade A. A.¹,Wyant T.¹,Parikh A.³,Sandborn W. J.⁴,Feagan B. G.⁵,Reinisch W.⁶⁷,Fox I.¹

Affiliation:

1. Takeda Pharmaceuticals International Co.; Cambridge MA USA

2. Metrum Research Group LLC; Tariffville CT USA

3. Takeda Pharmaceuticals International, Inc.; Deerfield IL USA

4. Division of Gastroenterology; University of California San Diego; La Jolla CA USA

5. Robarts Research Institute; University of Western Ontario; London ON Canada

6. Department Internal Medicine III; Medical University of Vienna; Vienna Austria

7. Department of Internal Medicine; McMaster University; Hamilton ON Canada

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.13243/fullpdf

Reference34 articles.

1. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases;Soler;J Pharmacol Exp Ther,2009

2. Pharmacokinetics of adalimumab in inflammatory bowel diseases: a systematic review and meta-analysis;Paul;Inflamm Bowel Dis,2014

3. Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms;Ordas;Clin Pharmacol Ther,2012

4. Therapeutic drug monitoring of biologics for inflammatory bowel disease;Colombel;Inflamm Bowel Dis,2012a

5. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin;Feagan;Clin Gastroenterol Hepatol,2008

Cited by 221 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Population pharmacokinetic modeling of vedolizumab for graft‐versus‐host disease prophylaxis in adults with allogeneic hematopoietic stem cell transplant;Pharmacology Research & Perspectives;2024-09-04

2. Recommendations on the management of severe obesity in patients with inflammatory bowel disease of the Spanish Group on Crohn’s Disease and Ulcerative Colitis (GETECCU), Spanish Society of Obesity (SEEDO), Spanish Association of Surgery (AEC) and Spanish Society of Digestive Endoscopy (SEED);Gastroenterología y Hepatología (English Edition);2024-08

3. Model-informed precision dosing: State of the art and future perspectives;Advanced Drug Delivery Reviews;2024-08

4. Mathematical Modeling of Vedolizumab Treatment’s Effect on Microbiota and Intestinal Permeability in Inflammatory Bowel Disease Patients;Bioengineering;2024-07-12

5. The Future of Clinical Trials in Inflammatory Bowel Disease;Clinical Gastroenterology and Hepatology;2024-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3